Compare Johnson & Johnson (JNJ) vs Vivmark Residential Common Shares of Beneficial Interest (VMRK) Price & Performance

Johnson & JohnsonTrade

Vivmark Residential Common Shares of Beneficial InterestTrade

Price performance (Past 24H)

Key statistics

Johnson & Johnson vs Vivmark Residential Common Shares of Beneficial Interest — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Vivmark Residential Common Shares of Beneficial Interest trades at $61.16 (market cap $46.41B). The key difference: Johnson & Johnson is far larger — about 13.3× Vivmark Residential Common Shares of Beneficial Interest's market cap, and Vivmark Residential Common Shares of Beneficial Interest pays the higher dividend (4.68%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Vivmark Residential Common Shares of Beneficial Interest for 1 Days on average.

	JNJ	VMRK
Market Cap	$618.09B	$46.41B
Volume	6,050,983	6,584,008
Sector	Health	Real Estate
52-Week High	$278.43	$70.15
52-Week Low	$186.00	$57.98
Typical Hold Time	129 Days	1 Days
Enterprise Value	$646.37B	$55.52B
Dividend Yield	2.09%	4.68%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.

JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.

Vivmark Residential Common Shares of Beneficial Interest

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

JNJ

82% Buy18% Sell

Avg holding period · 129 Days

VMRK

No sentiment data available yet.

Top news

Latest headlines on both assets

JNJ

Johnson & Johnson Q3 earnings expected with 5% EPS drop but 5.8% revenue growthGordon Thompson · 17 hours agoNeutral Four Dividend Kings remain strong but PepsiCo's dividend payout is riskier than others.24/7 Wall Street · 20 hours agoNeutral New Phase 3 data show ICOTYDE provides lasting skin clearance in moderate-to-severe plaque psoriasis over two years.PRNewsWire · 21 hours agoBullish View details →

VMRK

Apartment supply tightens after 3 years, boosting prospects for 4 key REITs with varied market positions.24/7 Wall Street · 15 hours agoBullish View details →

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

About Vivmark Residential Common Shares of Beneficial Interest

Vivmark Residential is a residential real estate investment trust that owns and operates apartment communities in U.S. markets. Its portfolio includes apartment homes and development projects.